Selank
Also known as TKPRPGP, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TP-7, Selank acetate
A seven-amino-acid tuftsin analogue. Its patient studies are small, Russian and without placebo; FDA lists it as a withdrawn compounding nomination.
Selank has been tested in patients only in four small Russian studies of anxiety disorders, read here as English abstracts. None of those patient studies had a placebo arm, and none of the abstracts read states randomisation or blinding. Two compared selank with a benzodiazepine, medazepam (source) or phenazepam (source); one added it to phenazepam (source); one measured laboratory markers (source). The only study in healthy volunteers measured brain connectivity by fMRI and reports no result for selank alone (source). Searches found no registered trial and no systematic review. Russian registration is not established: the only source found is a table in a 2022 review (source). FDA lists selank among withdrawn compounding nominations (source), and it was on no advisory committee agenda found.
What it is
Selank is a chain of seven amino acids, Thr-Lys-Pro-Arg-Pro-Gly-Pro, or TKPRPGP (source). Its formula is C33H57N11O9 and its molecular weight 751.9 (source). It is a synthetic analogue of tuftsin, a four-amino-acid fragment (Thr-Lys-Pro-Arg) of the human immunoglobulin G heavy chain, lengthened by Pro-Gly-Pro (source).
That Pro-Gly-Pro tail is the only structural link with semax, which has a different sequence, a different literature and a different FDA history. FDA's table names "Selank acetate (TP-7)" without giving a salt ratio, so it is not assumed here to match any particular salt form. N-acetyl selank is a different substance and is not covered here.
Anxiety studies
In 62 patients with generalised anxiety disorder or neurasthenia, selank (30 patients) and medazepam (32 patients) were scored on the Hamilton, Zung and CGI scales, and the authors call the anxiolytic effects "similar" (source). In 60 patients with phobic-anxiety and somatoform disorders, a comparison with phenazepam reports "mild nootropic effects" without naming a cognitive test, and gives no result for phenazepam (source).
Cognition and the brain
The placebo-controlled study in 52 healthy participants measured resting-state amygdala connectivity, not memory or attention, and grouped selank with semax in its conclusions (source). In rat frontal cortex, selank or GABA changed the expression of 45 genes, with no count for selank alone, and the authors propose an effect on the GABA system (source); in a human neuroblastoma cell line, "We found no changes in the mRNA levels of the genes studied" (source).
In animals and cells
In rats on the elevated plus maze, selank reduced anxiety-like behaviour, alone or with diazepam (source). In laboratory animals infected with influenza A, mice according to the record's indexing, pre-treatment raised survival (source). In mouse spleen, it lowered complement C3 mRNA 3-fold (source). These are transcription and animal findings, not evidence of immune benefit in people.
Regulatory position
FDA lists "Selank acetate (TP-7)" among bulk substances nominated for compounding but withdrawn (source). It was not on the July 2026 advisory committee agenda (source) or the one scheduled before February 2027 (source), and a text search of the 503A list of 14 May 2026 found no entry (source). Its status under anti-doping rules was not established from a primary document.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Human case reportInsufficient evidence / Very low confidence
In 62 patients with generalised anxiety disorder or neurasthenia, selank (30 patients) was compared with the benzodiazepine medazepam (32 patients) on the Hamilton, Zung and CGI scales, and the authors report similar anxiolytic effects, with no placebo arm.
Zozulia and colleagues (2008) write that "The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects." They also measured enkephalin activity in blood serum, a laboratory marker. The abstract gives no scores or p-values.
One or a few individual cases. Cannot show whether an effect is general.
- Two active drugs judged similar, without a placebo arm or a stated non-inferiority design, cannot show that either worked.
- PubMed tags the study as a randomised controlled trial, but the abstract does not mention randomisation or blinding. The Hamilton variant and the duration are not stated.
- Russian-language paper; only the English abstract was read.
- Human case reportInsufficient evidence / Very low confidence
In 60 patients with phobic-anxiety and somatoform disorders, a comparison of selank with the benzodiazepine phenazepam reports anxiolytic and "mild nootropic" effects of selank, without naming a scale, a cognitive test or a result for phenazepam.
Medvedev and colleagues (2014) report "Pronounced anxiolytic and mild nootropic effects of selank" and that "The anxiolytic effect lasted for a week after last receiving the peptide." Arm sizes, scales and duration are not given in the abstract.
One or a few individual cases. Cannot show whether an effect is general.
- No comparison with phenazepam is reported in the abstract, and no cognitive test is named for the nootropic statement.
- Randomisation and blinding are not mentioned. Abstract only.
- Human case reportInsufficient evidence / Very low confidence
In anxiety-phobic, hypochondriac and somatoform disorders, adding selank to phenazepam (40 patients) against phenazepam alone (30 patients) is reported to bring forward improvement on the HDRS and to reduce phenazepam's side effects on the UKU scale.
Medvedev and colleagues (2015) used the HDRS, CGI and Spielberger scales, the UKU side-effect scale, the Stroop and verbal fluency tests and the SF-36. They report that the combination "decreased the level of undesirable side-effects of phenazepam". Stroop and verbal fluency results are not given in the abstract.
One or a few individual cases. Cannot show whether an effect is general.
- An add-on design tests selank with a benzodiazepine, not selank on its own.
- PubMed tags it as a randomised controlled trial; the abstract does not mention randomisation or blinding. Arms are unequal and the abstract does not explain why the HDRS, usually a depression scale, was used.
- Human case reportInsufficient evidence / Very low confidence
In 52 healthy participants given selank, semax or placebo, the only placebo-controlled human study found measured resting-state fMRI connectivity of the amygdala and prefrontal cortex, and its abstract attributes no result to selank alone.
Panikratova and colleagues (2020) scanned participants before and 5 and 20 minutes after administration and report connectivity differences between the right amygdala and temporal regions, describing "general and specific effects of Selank and Semax". No anxiety or cognitive measure was reported.
One or a few individual cases. Cannot show whether an effect is general.
- Arm sizes, randomisation and blinding are not stated in the abstract.
- A change in a resting-state network is a surrogate, not a change in anxiety or thinking.
- Animal researchSupportive / Low confidence
In rats and mice under conflict stress, and in rats on the elevated plus maze, selank is reported to reduce anxiety-like behaviour, alone or with diazepam.
Kozlovskaya and colleagues (2003) report that tuftsin peptides and selank "were shown to have positive emotional effects and antistress actions" in rats and mice. Kasian and colleagues (2017) found selank alone most effective for anxiety induced by the drug course itself, and diazepam plus selank most effective under unpredictable chronic mild stress.
Observed in animals. Animal results frequently fail to replicate in humans.
- Group sizes and selank-specific figures are not in the abstracts. Most of this work comes from Russian research groups.
- Animal researchSupportive / Low confidence
In cell culture and mice infected with influenza A (H3N2), selank given before infection is reported to suppress viral reproduction and raise survival; there are no human infection data.
Ershov and colleagues (2009) report "completely suppressing viral reproduction" in cell culture when selank was added 24 hours before inoculation, and the "highest survival of laboratory animals" with pre-treatment. No figures are given in the abstract.
Observed in animals. Animal results frequently fail to replicate in humans.
- Mouse and cell-culture work. It does not show that selank prevents influenza in people.
- In-vitroSupportive / Low confidence
In test-tube studies with human plasma and serum enzymes, selank inhibited enkephalin-degrading enzymes at micromolar concentrations, with two IC50 values reported by the same group: 15 µM and 20 µM.
Zozulya and colleagues (2001) report an IC50 of 15 µM in plasma; Kost and colleagues (2001) report 20 µM with serum enzymes. No human pharmacokinetic study was found, so whether these concentrations are reached in the body is unknown.
Observed in cells or tissue outside a living organism.
- The two values differ, from different enzyme preparations in the same group's work.
- Mechanistic reasoningInsufficient evidence / Very low confidence
Immune findings in people are laboratory markers: in blood from patients with depression, selank suppressed IL-6 gene expression in cell culture, and patients with generalised anxiety disorder or neurasthenia given selank for 14 days showed shifts in Th1/Th2 cytokine balance.
Uchakina and colleagues (2008) report that selank "completely suppressed gene expression" of IL-6 in blood cells of patients with depression but not healthy controls, yet also a significant increase in IL-6 concentration in the same cell culture. No infection or clinical immune outcome was measured.
A plausible biological explanation, not a measured outcome.
- The abstract reports IL-6 mRNA falling while IL-6 protein rose; it does not reconcile the two.
- The number of patients and any control group for the 14-day part are not stated.
- Mechanistic reasoningInsufficient evidence / Low confidence
In mouse spleen, selank changed the expression of inflammation-related genes, including a 3-fold fall in complement C3 mRNA 30 minutes after injection; this is a measure of transcription, not of immunity.
Kolomin and colleagues (2011) report "significant changes in the expression of 34 genes" of 84 studied. In 2014 they report "a significant 3-fold decrease in the C3 mRNA level just 30 min after Selank injection", with a similar change from its Gly-Pro fragment.
A plausible biological explanation, not a measured outcome.
- Mouse tissue; group sizes are not in the abstracts.
- Mechanistic reasoningContradictory / Very low confidence
Evidence that selank acts through the GABA system is conflicting gene-expression data: in rat frontal cortex, selank or GABA changed the expression of 45 genes, while a human neuroblastoma cell line showed none; no study measured GABA-A receptor binding or function.
Volkova and colleagues (2016) report "significant changes in the expression of 45 genes 1 h after the administration of the compounds", selank or GABA, in rat frontal cortex, with no count given for selank alone, and propose "allosteric modulation of the GABAergic system". Filatova and colleagues (2017), in IMR-32 human neuroblastoma cells, write: "We found no changes in the mRNA levels of the genes studied under the effect of Selank."
A plausible biological explanation, not a measured outcome.
- The claim that selank acts on GABA-A receptors is a hypothesis, not a finding, in the sources found.
Reported and theoretical risks
- Mechanismunknown
Immunogenicity and impurities in compounded products
FDA states that "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration" "due to the potential for aggregation and peptide-related impurities." and that "FDA lacks important information regarding any safety issues raised by selank acetate administered to humans."
- Case reportunknown
Tolerability statements come from studies not designed to detect harm
The comparison with phenazepam studied tolerability but its abstract reports no adverse events, and the add-on study used the UKU side-effect scale without reporting selank's own adverse events. Searches found no case report, no adverse event database record and no human pharmacokinetic study. Absence of reported harm in small uncontrolled studies is not evidence of safety.
- Animaltheoretical
Interaction with benzodiazepines not characterised in people
In rats, selank changed the anxiety response to diazepam, and in patients it was given alongside phenazepam. How selank alters benzodiazepine effects in people has not been characterised in the sources found.
- In-vitrotheoretical
Shift in neuron development in mouse embryonic stem cells
In mouse embryonic stem cells, selank reduced the share of GABA-positive neurons by 61% against control at the concentration tested. The authors conclude there is no toxic effect in embryonic and fetal life, which one cell model cannot establish. No reproductive, developmental, repeat-dose, genotoxicity or carcinogenicity study was found.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAnot approved
FDA lists "Selank acetate (TP-7)" in the table "Bulk drug substances nominated but withdrawn", stating: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans."
As of 22 April 2026. Source
USFDAnot approved
FDA's 503A categories list updated 29 September 2023 added "Selank Acetate (TP-7)" to category 2, stating that "The following substances will be added to Category 2 because FDA has identified significant safety risks with these substances". The copy of the 2023 list read for this page is hosted by a trade association, not by FDA.
As of 29 September 2023. Source
USFDAunclear
Selank does not appear on the agenda of FDA's Pharmacy Compounding Advisory Committee meeting of 23-24 July 2026. No FDA briefing document on selank was found.
As of 6 August 2026. Source
USFDAunclear
Selank does not appear on the agenda of the Pharmacy Compounding Advisory Committee meeting FDA lists for before the end of February 2027.
As of 15 April 2026. Source
USFDAunclear
A text search of FDA's 503A bulk drug substance categories list updated on 14 May 2026 found no entry for selank in any category.
As of 14 May 2026. Source
RUState Register of Medicines (as reported in a 2022 review)unclear
Second hand: a 2022 narrative review lists selank, as an anxiolytic, in Table 1, "Peptide drugs developed in Russia and their clinical and pharmacological groups", and states that "14 products are registered in the Russian Federation". It gives no registration number, date, holder or indication, and this site could not retrieve a Russian register entry, so Russian registration is not established here.
As of 11 October 2026. Source
Research and analysis
Related peptides
- SemaxA seven-amino-acid ACTH fragment analogue that FDA reports is registered in Russia
Sources
- 1. Zozulia AA et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. PubMed 18454096
- 2. Medvedev VE et al. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014. PubMed 25176261
- 3. Medvedev VE et al. [Optimization of the treatment of anxiety disorders with selank]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015. PubMed 26356395
- 4. Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020. PubMed 32342318
- 5. Uchakina ON et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. PubMed 18577961
- 6. Kozlovskaya MM et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and Behavioral Physiology. 2003. PubMed 14969422
- 7. Kasian A et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017. PubMed 28280289(open access)
- 8. Ershov FI et al. [Antiviral activity of immunomodulator Selank in experimental influenza infection]. Voprosy virusologii. 2009. PubMed 19882898
- 9. Kolomin T et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides. 2011. PubMed 21609736
- 10. Kolomin T et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Molecular Immunology. 2014. PubMed 24291245
- 11. Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016. PubMed 26924987(open access)
- 12. Filatova E et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017. PubMed 28293190(open access)
- 13. Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001. PubMed 11550013
- 14. Kost NV et al. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorganicheskaia khimiia. 2001. PubMed 11443939
- 15. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 16. Kobylyanskii AG et al. Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells. Bulletin of Experimental Biology and Medicine. 2017. PubMed 29063333
- 17. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Updated September 29, 2023). U.S. Food and Drug Administration (copy hosted by the Alliance for Pharmacy Compounding). 2023. View source(open access)
- 18. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. View source(open access)
- 19. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. View source(open access)
- 20. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 21. Deigin VI et al. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022. PubMed 35456550(open access)